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Graves' disease is a hypermetabolic state accompanied with an increase in the total
consumption of oxygen, which results in increased formation of reactive oxygen species
and other free radicals, or the occurrence of oxidative stress (1–4). Namely, in a small
number of experimental clinical studies, the existence of oxidative stress in hyperthy-
roidism was confirmed by determining different parameters. Some investigators have
studied changes in the parameters of oxidative defence in the thyroid gland tissue of
patients with hyperthyroidism (5, 6). Treatment with propylthiouracil (PTU) for three
months only partially resulted in balanced antioxidative activity, as compared to the
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In this study, the effect of supplementation with a fixed
combination of antioxidants (vitamins C and E, -caro-
tene and selenium) on concentrations of antioxidative
parameters in serum was monitored. Measurements were
performed prior to the commencement of therapy and af-
ter 30 and 60 days in patients with Graves' disease treated
with methimazole. Patients who received extra supple-
mentation with antioxidants (group A, n = 29) attained
euthyroidism faster than the patients treated only with
methimazole (group B, n = 28). Statistically significant
differences were achieved after supplementation with
antioxidants for all investigated parameters (uric acid,
transferrin, ferritin), except TAS and glucose. Neverthe-
less, due to the fact that all measured parameters remain-
ed within the range of referent values, they may not be
proposed as reliable indicators of the level of oxidative
stress in Graves' disease.
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control group (7). Komosinska-Vassev and coworkers (8) carried out an investigation
into the activity of free radicals and antioxidative defence in patients with Graves' disease,
during methimazole therapy. In untreated patients, an increase in lipid peroxidation and
the activity of cellular antioxidative enzymes was detected in comparison with the con-
trol group, with simultaneous lowering of extracellular antioxidative parameters and
total antioxidant status (TAS). Disturbed antioxidative defence indicates the possible
usefulness of supplementation with antioxidants, aimed at preventing the occurrence of
oxidatively damaged tissues in patients with Graves' disease.
An investigation on an experimental model of hyperthyroidism in animals demon-
strated the useful effect of supplementation with vitamin E (9).
Clinical investigations of the effect of particular antioxidants in the treatment of
Graves' disease are scarce and the results are partially contradictory. Seven and cowork-
ers (10) examined the effect of supplementation with vitamin C on oxidative stress in
hyperthyroid patients treated with PTU. The results show that additional application of
vitamin C strengthens the antioxidative defence and consequently lowers the degree of
oxidative stress. On the other hand, a study by Adali and coworkers (11) on the effect of
PTU, propranolol and vitamin E on lipid peroxidation and antioxidative status in
patients with hyperthyroidism failed to show any additional positive effect of vitamin E.
Investigations published to date on the effect of applying a combination of antioxi-
dants in the treatment of Graves' disease provide encouraging results (12, 13). Results of
these studies indicate the effectiveness of supplementation with antioxidants in the
treatment of Graves' disease.
In the present study, we have attempted to evaluate the effect of supplementation
with a fixed combination of antioxidants, available on the market, on some extracellular
antioxidative parameters such as urates, transferrin, ferritin, glucose, and TAS, as an
indicator of the total strengthening of the antioxidative defence of the organism. These
antioxidants are supposed to have the ability to neutralise free radical action.
EXPERIMENTAL
Subjects
The study consisted of a group of 57 patients with newly detected Graves' disease
from the Department of Nuclear Medicine and the Department of Endocrinology of the
Dubrava University Hospital (Zagreb, Croatia).
The patients were randomly divided into two groups. Group A (n = 29, 25 women
and 4 men) took methimazole (Athyrazol, Jadran Galenski Laboratorij), 120 mg daily for
the first weeks, 80 mg daily the second week, 60 mg daily the third and fourth week, 40
mg daily for the following four weeks, plus an additional daily capsule of a fixed combi-
nation of pharmacological antioxidants: 6 mg -carotene, 200 mg C vitamin, 36 mg E vi-
tamin and 60 g Se (Symbion, Merck, Germany). Group B (n = 28, 27 women and 1 man)
took only methimazole, at the same doses as group A. More than 60% of the patients
were aged 30 to 45 years.
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The patients were examined prior to the commencement of therapy, after 30 and 60
days. Apart from a clinical examination of the patient, ultrasound of the thyroid gland
was performed and a blood sample was taken. Graves' disease was diagnosed on the
basis of the clinical status, ultrasound findings, reduced activity of the thyroid stimu-
lating hormone (TSH) and increased concentration of the free fraction of T3 and T4 hor-
mones, compared to referent values. Criteria for exclusion of patients from the study
were the presence of other chronic and acute diseases, or conditions requiring applica-
tion of other drugs or additional vitamins and minerals.
Questionnaires were completed with data on patients' age, sex, body mass and
height, nutritive habits, smoking and previous health status.
None of the patients in either group had special nutritive habits such as avoidance
of certain types of food for religious or other reasons, and none of the patients were ve-
getarians. None of the patients had previously suffered from any serious infections or
other diseases.
Informed consent was obtained from all the participants in the study. The study
protocol was approved by the Ethics Committee of the Dubrava University Hospital
(Zagreb, Croatia) and was carried out in accordance with the ethical guidelines of the
Helsinki Declaration.
Laboratory analysis
Fasting samples of venous blood were collected between 8.00 and 10.00 A.M. for
analyses of the free fraction of thyroid hormones (FT4, FT3), TSH, ferritin, transferrin,
glucose, uric acid and TAS. Serum samples were stored in polyethylene Eppendorff test
tubes at –20 °C until analysis.
Concentrations of FT4 and FT3 and TSH activity were determined by the chemilu-
minescence method on a Vitros Eci analyser (Ortho-Clinical Diagnostic, UK) using the
test package (C1387000 for FT4, C1315589 for FT3, C1912997 for TSH) of the same ma-
nufacturer.
TAS was determined with Randox test kits (Randox, UK; TAS NX2332). The pro-
cedure precision and accuracy were controlled using the respective control specimens of
the same manufacturer: Randox Total Antioxidant Control (Cat.No.NX 2331). All para-
meters were determined on an Olympus AU500 analyser (Olympus Co., Japan), with
test kits of the same manufacturer.
Statistical analysis
Significance of the changes in the selected parameters was tested within each group:
prior to the commencement and on the 30th and 60th day after the commencement of
therapy, and between each measurement of both examined groups. Significance of the
difference between the results was determined by means of the Friedman ANOVA non-
parametric analysis of variance for independent samples, Wilcoxon’s nonparametric test
for dependent samples (within groups A and B), and Mann-Whitney’s nonparametric
test for independent samples (between groups A and B).
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RESULTS AND DISCUSSION
The degree of cell damage in Graves' disease is in direct correlation with the level of
oxidative stress, which depends on the efficacy of the applied therapy and the capacity
of the antioxidant defence of the organism. A speedy recovery is important for all pa-
tients, particularly in some categories, such as pregnancy and cardiomyopathy. In this
context, the role of the free radical scavengers can be extremely important.
Uric acid
The concentration of uric acid in serum was within the wide range of referent va-
lues (90–420 mol L–1) during the treatment, but it decreased significantly in both groups
of patients (group A: p < 0.05, group B: p < 0.01). A statistically significant difference was
found between the groups 60 days after the commencement of therapy (p < 0.05) (Fig. 1).
Uric acid acts as an extracellular antioxidant because of its ability to remove singlet
oxygen, hydroxyl and peroxyl radical. Sato et al. (14) registered this phenomenon of an
increased level of uric acid in the serum of patients with untreated Graves' disease. In a
group of 92 patients with Graves' disease, an increased concentration of uric acid in se-
rum was determined, which correlated well with the concentration of thyroid hormones.
The concentration of uric acid decreased with treatment and was in positive correlation
with the clearance of uric acid and increased blood flow through the kidneys. The ratio
of uric acid clearance and glomerular filtration was within the range of referent values
and similar to the ratio in the control group of healthy subjects. The concentration of
uric acid in the serum of patients with hypothyroidism was lower compared to the con-
trol group and increased with treatment, within the same study. Raised concentration of
uric acid may be a consequence (if nutritional factor is ruled out) of increased purine
synthesis, on the one hand, or increased degradation of puric nucleotides or decreased
secretion on the other.
In our study, we were able to rule out decreased secretion as the reason for the in-
creased concentration of uric acid in the serum prior to the commencement of therapy.
Thus, we considered the effect of the state of intensified metabolism and catabolism,
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Fig. 1. Concentration of uric
acid in serum (median box:
25–75%, bars: min – max).
Statistical significance of the
difference between the groups
at the same time points: NS –
not significant, b – p < 0.05.
such as in Graves' disease, on the concentration of uric acid. However, the question can
also be raised as to whether the increased concentration of uric acid in hyperthyroidism
is a consequence of the response of the organism to oxidation stress and mobilisation of
protective antioxidative mechanisms, or not. It is interesting to note that the oxidation
activity of uric acid, with respect to function, is identical to the activity of ascorbic acid.
The biosynthesis of ascorbic acid is extinguished in man and higher primates, parallel
with gene expression for uricase. This evolutionary phenomenon has been explained by
the following provocative hypothesis. Effective synthesis and maintenance of a high
concentration of uric acid, which is energetically more rational than ascorbate biosyn-
thesis, is an essential precondition for successful protection from the harmful action of
free radicals of several types. Humans and higher primates are cumulatively most ex-
posed, not only because of the aerobic metabolism but also because of the life span (15).
According to this hypothesis, an increased concentration of uric acid in serum would be
the response of the organism to oxidation stress. Thus, this would explain the significant
decrease in the concentration of uric acid during treatment of patients in both groups in
the present study. After 60 days of therapy, the concentration of uric acid in group B was
significantly lower compared to group A, which points to the effect of supplementation
with antioxidants. This phenomenon may perhaps be explained by the effect of the rate
of »consumption« of uric acid on neutralisation of free radicals in the serum of patients
in whom there were no free radical scavengers. We consider that further study is ne-
cessary to better understand the above complex phenomenon.
Transferrin and ferritin
During the treatment, the concentration of transferrin in serum was within the
range of the referent values (2.0–3.8 g L–1) but increased significantly in both groups of
patients (p < 0.01). A statistically significant difference was also found between groups A
and B 60 days after the commencement of therapy (p < 0.05) (Fig. 2).
In contrast, concentration of ferritin in serum (referent values 10–300 ng mL–1) de-
creased significantly in both groups (p < 0.001) during the treatment, and a statistically
significant difference between the groups was observed 60 days after the commence-
ment of therapy (p < 0.001) (Fig. 3).
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Fig. 2. Concentration of trans-
ferrin in serum (median box:
25–75%, bars: min – max). Sta-
tistical significance of the dif-
ference between the groups at
the same time points: NS –
not significant, b – p < 0.05.
Transferrin and ferritin have antioxidative characteristics due to their ability to bind
iron. Iron, along with copper, is the most important transfer metal, which participates in
the reactions between oxidants and antioxidants. In Fenton's reaction, Fe2+ and Cu+
change to a higher oxidative state, when the exceptionally reactive hydroxyl radical de-
velops from hydrogen peroxide. Hydroxyl radical also develops from superoxide radical
and hydrogen peroxide, with free ions of Fe2+ and Cu+ in the Haber-Weiss reaction. Hy-
droxyl radicals can further induce lipid peroxidation and thus cause changes in the nu-
cleal and cytoplasmic membrane. Consequently, the mechanisms that control and re-
duce the catalytic ability of these metals are important. The amounts of free ions of iron
and copper are minimal, while the remainder is bound to proteins, transferrin, ferritin
and ceruloplasmin.
Transferrin is the most important protein for the transfer of iron in the organism. In
normal human plasma, only 20–30% of transferrin is saturated with iron, and conse-
quently plasma almost completely lacks free iron. Bound iron cannot take part in the
reactions during the formation of the highly reactive hydroxyl radical. Ferritin is a pro-
tein for the storage of iron in cytosol. It can bind up to 4500 iron ions per molecule. Iron
enters ferritin as Fe2+ and deposits as Fe3+ and hence it has a protective role in cytosol.
The raised concentration of ferritin in serum, which decreases with treatment, has
been described in several studies concerning hyperthyroidism (16, 17). This increase in
the level of ferritin in serum can be explained by the response of the organism to oxi-
dative stress. As the level of oxidative stress decreases with the treatment, the level of
ferritin also drops. In this respect, it should not be forgotten that ferritin in serum has no
longer an antioxidative effect. Some authors suggest that the raised level of ferritin in
the serum of patients with hyperthyroidism is a result of the direct action of the thyroid
hormones themselves on its synthesis (16, 17). This mechanism may also explain the
raised level of ferritin in serum before treatment and its decrease during treatment, as
recorded in our patients. The significant difference in the ferritin concentration between
groups A and B, 60 days after the commencement of therapy, indicates the possible ad-
ditional effect of antioxidants. The lower level of ferritin in the serum of patients in
group B, who did not receive antioxidants, can be explained by the faster »consump-
tion« of ferritin in the cells. Possibly, the lack of supplementation with pharmacological
antioxidants was one of the reasons for the significant increase in the level of transferrin
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Fig. 3. Concentration of ferri-
tin in serum (median box:
25–75%, bars: min – max).
Statistical significance of the
difference between the groups
at the same time points: NS –
not significant, a – p < 0.001.
in the serum of patients in group B, as a result of a compensatory mechanism. We are
inclined to believe that the described changes in transferrin and ferritin cannot be ex-
plained merely in the context of oxidative stress and antioxidative defence, but rather in
terms of the general development of hyperthyroidism and its consequence on the orga-
nism.
Glucose
In both groups of patients, the concentration of glucose in serum was within the
range of referent values (3.6–5.5 mmol L–1). It did not change significantly either within
each group or between the groups during the therapy (Fig. 4).
Theoretically, glucose can act as an antioxidant because of its ability to bind free
ions of iron and copper and remove the hydroxyl radical (18). However, the results of
our study did not show any significant changes. We can therefore conclude that the con-
centration of glucose cannot be used as a sufficiently sensitive indicator of antioxidative
defence in a clinical examination of this type.
TAS
During the treatment, the concentration of TAS in serum (referent value 1.5 mmol
L–1) increased significantly in both groups (group A: p < 0.05, group B: p < 0.01); no sta-
tistically significant difference was found between the groups (Fig. 5). Similar results
were obtained in a few studies that investigated this indicator in Graves' disease. In the
investigation done by Komosinske-Vassev (8), a higher concentration of TAS was found
in the serum of patients with Graves' disease after therapy with methimazol and attain-
ment of euthyreosis, compared to the state prior to the commencement of treatment.
However, the concentration of TAS in euthyreotic patients under therapy, compared to
the values of TAS in subjects in the control (healthy) group, was still lower. This lower
level of extra-cellular total antioxidation potential in untreated patients indicated the le-
vel of oxidation stress, which was higher prior to the commencement of therapy. The ex-
istence of differences in the level of TAS in the serum of euthyreotic patients compared
to healthy subjects may indicate the relative slowness in the rate of the change of this in-
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Fig. 4. Concentration of glu-
cose in serum (median box:
25–75%, bars: min – max). NS
– not significant differences
between the groups at the
same time points.
dicator. A certain slowness and also the fact that thiol groups of albumins contribute
most to TAS may be the reason for the non-existence of significant differences in the TAS
values between our groups of patients.
Thyroid hormones and TSH
Concentration of FT4 in serum, which was above the upper limit of referent values
(10.0–28.2 pmol L–1) prior to commencement of treatment, gradually decreased in both
groups of subjects. In both groups, we observed, a statistically significant decrease in the
concentration of hormone FT4 in serum during the study (p < 0.001). A statistically sig-
nificant difference between the groups was observed 30 (p < 0.001) and 60 days (p < 0.005)
after the commencement of therapy (Table I).
During the treatment, the concentration of FT3 hormone in serum, which was above
the upper limit of referent values (4.7–8.0 pmol L–1) prior to the commencement of treat-
ment, decreased in both groups. Statistically significant differences (p < 0.001) were found
within each group. However, a statistically significant difference between the groups
was evaluated only after 30 days (p < 0.001) (Table I).
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Fig. 5. Concentration of TAS in
serum (median box: 25–75%,
bars: min – max). NS – not
significant difference between
the groups at the same time
points.
Table I. Concentrations of FT4, FT3 and activity of TSH in seruma
Parameter FT4 (pmol L–1) FT3 (pmol L–1) TSH (mU L–1)








































Absolute values are expressed as the median (min–max). Statistical significance of the difference between the
groups at the same time point: b p < 0.001; c p < 0.01; d p < 0.05; NS not significant.
a For more information see reference 13.
During the study, a statistically significant increase in TSH activity (referent values
0.47–4.68 mU L–1) was determined only in group A (p < 0.001). Comparison of the
groups shows that a statistically significant difference was observed only 60 days after
the commencement of therapy (p < 0.05) (Table I).
Based on the results obtained it can be concluded that patients in group A, who re-
ceived additional therapy with pharmacological antioxidants, exhibited a significantly
different decrease of FT4 and FT3 concentration and a significant increase of TSH activity
in serum, and thus attained euthyroidism more rapidly, compared to patients in group
B. The statistically significant difference between groups A and B with regard to the
speed of attaining euthyroidism indicates the favourable effect of additional therapy
with pharmacological antioxidants, vitamin E, vitamin C, -carotene and selenium.
Pharmacological antioxidants may affect the peripheral conversion of thyroid hor-
mones by way of deiodination and/or mechanism of cell membrane defence, the inte-
grity of which can have an effect on the activity of deiodinases (19, 20).
CONCLUSIONS
Application of the fixed combination of antioxidants accelerated normalisation of
the thyroid hormone values and thus shortened the period of exposure of the organism
to oxidation stress. There was no significant change in the concentration of glucose in se-
rum in either group during the treatment, although theoretically glucose could be a use-
ful natural antioxidant. The concentration of TAS in serum significantly increased during
the treatment, though there was no significant difference between the groups, and thus
it cannot be considered a sufficiently sensitive indicator of the level of oxidative stress.
Although the concentrations of uric acid, transferrin and ferritin significantly differed
between the groups during the treatment, they cannot be considered sufficiently reliable
indicators of extracellular non-enzymatic antioxidative defence of the organism, either
for several reasons: the wide range of referent values (uric acid), the fact that the mea-
sured values, though significantly changed during treatment, were within the physio-
logical ranges, and the fact that their primary role in the organism is not antioxidative
defence. Further targeted investigations in this respect are needed in order to clarify the
nature of the described changes.
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S A @ E T A K
Suplementacija s antioksidansima u terapiji Graves-ove bolesti: u~inak na
ekstracelularne antioksidativne parametre
VESNA BACIC VRCA, FRANJO SKREB, IVANA CEPELAK i LJILJANA MAYER
U ovom istra`ivanju promatran je u~inak suplementacije fiksnom kombinacijom an-
tioksidansa (vitamini C i E, -karoten i selen) na koncentracije pokazatelja antioksi-
dacijske obrane u serumu. Mjerenja su obavljena u bolesnika s Graves-ovom bole{}u lije-
~enih metimazolom (tiamazolom) prije po~etka terapije, te nakon 30 i 60 dana. Bolesnici,
koji su uz metimazol imali i dodatnu terapiju s antioksidansima (skupina A, n = 29),
postizali su eutireozu br`e od bolesnika koji su bili samo na terapiji metimazolom (sku-
pina B, n = 28). Koncentracije svih mjerenih parametara (urata, feritina i transferina),
(osim koncentracije TAS-a i glukoze), zna~ajno su se razlikovale me|u skupinama. Una-
to~ tomu, rezultati ove studije ukazuju na to kako se odre|ivani parametri ne mogu
smatrati dovoljno pouzdanim pokazateljima razine oksidacijskog stresa u Graves-ovoj
bolesti, radi ~injenice da su njihove koncentracije tijekom ispitivanja ostale unutar gra-
nica referentnih vrijednosti.
Klju~ne rije~i: Graves-ova bolest, antioksidansi, feritin, TAS, transferin, urati
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